Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Accelerating global innovation to address antibacterial resistance: introducing CARB-X

Abstract

A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations http://amr-review.org (2016).

  2. 2

    Laxminarayan, R. et al. Antibiotic resistance—the need for global solutions. Lancet Infect. Dis. 13, 1057–1098 (2013).

    Article  Google Scholar 

  3. 3

    Rex, J. H. & Outterson, K. Antibiotic reimbursement in a sales-delinked model: context and a benchmark-based global approach. Lancet Infect. Dis. 16, 500–505 (2016).

    Article  Google Scholar 

  4. 4

    Outterson, K. New business models for sustainable antibiotics. Chatham House http://www.chathamhouse.org/publications/papers/view/197446 (2014).

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kevin Outterson.

Ethics declarations

Competing interests

J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals, non-executive board member, senior advisor and shareholder of F2G Pharmaceuticals; non-executive board member of Adenium Biotech ApS; Expert-in-residence, Wellcome Trust; and operating partner and consultant, Advent Life Sciences. P.J. is executive director of AMR Centre Ltd; non-executive director of Redx Pharma Plc; non-executive director of Yprotech Ltd; non-executive director of Biovictrix Therapeutics Ltd; and owner and director of Intelia Consulting.

Related links

Related links

FURTHER INFORMATION

CARB-X

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Outterson, K., Rex, J., Jinks, T. et al. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov 15, 589–590 (2016). https://doi.org/10.1038/nrd.2016.155

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing